1. "2022"
Formats
  1. Journal Article (2449)
  2. Meeting Abstract (2196)
  3. Review (615)
  4. Editorial (363)
  5. Book Section (139)
  6. Correspondence (117)
  7. Guidelines (112)
  8. Research Letter (82)
  9. Miscellaneous (60)
  10. Conference Paper (29)
  11. Book Whole (6)
Groups
  1. Department of Medicine (2621)
  2. Solid Tumor Oncology Division (1573)
  3. Sloan Kettering Institute Postdocs (1364)
  4. GSK Faculty (1152)
  5. Surgery (1036)
  6. Hematologic Malignancies, Division of (964)

More Groups

People
  1. Miguel-Angel Perales (95)
  2. Alexander Drilon (85)
  3. Saad Usmani (83)
  4. Sergio Giralt (77)
  5. Marc Ladanyi (72)
  6. Gilles Salles (69)

More People

Years
  1. 2022 (6168)
Publications
  1. Journal of Clinical Oncology (520)
  2. Blood (319)
  3. Cancer Research (191)
  4. Annals of Oncology (158)
  5. Annals of Surgical Oncology (134)
  6. International Journal of Radiation Oncology, Biology, Physics (132)

More Publications

Publishers
  1. Elsevier Inc. (794)
  2. American Society of Clinical Oncology (583)
  3. Springer (440)
  4. Nature Publishing Group (379)
  5. American Society of Hematology (369)
  6. Oxford University Press (360)

More Publishers

Results (6168)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Polatuzumab vedotin combined with R-ICE (PolaR-ICE) as second-line therapy in relapsed/refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Herrera, A. F.; Chen, L.; Crombie, J. L.; Cohen, J. B.; Advani, R. H.; LaCasce, A. S.; Popplewell, L. L.; Puverel, S.; Peters, L.; Daniels, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Relapse is uncommon in patients with large B-cell lymphoma who are in complete remission at the end of fixed-course glofitamab treatment
    Meeting Abstract

    Hutchings, M.; Carlo-Stella, C.; Morschhauser, F.; Bachy, E.; Corradini, P.; Iacoboni, G.; Khan, C.; Patel, K.; Hertzberg, M.; Falchi, L.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed / refractory Waldenström macroglobulinemia: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Palomba, M. L.; Patel, M. R.; Eyre, T. A.; Jurczak, W.; Lewis, D. J.; Gastinne, T.; Ma, S.; Cohen, J. B.; Patel, K.; Brown, J. R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Allogeneic but not autologous stem cell transplantation improves outcome in HTLV-1-associated North American adult T-cell leukemia/lymphoma
    Meeting Abstract

    Bazarbachi, A. H.; Reef, D. K.; Narvel, H.; Patel, R.; Al Hamed, R.; Thakkar, A.; Rahman, S.; Shah, U. A.; Herrera, D. A.; Quinn, R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma naïve to B-cell maturation antigen (BCMA)-directed therapies: Results from Cohort A of the MagnetisMM-3 study
    Meeting Abstract

    Bahlis, N. J.; Tomasson, M. H.; Mohty, M.; Niesvizky, R.; Nooka, A. K.; Manier, S.; Maisel, C.; Jethava, Y.; Martinez-Lopez, J.; Prince, H. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Wierda, W. G.; Lewis, D. J.; Ghia, P.; Shah, N. N.; Coombs, C. C.; Cheah, C. Y.; Lamanna, N.; Rhodes, J. M.; Hoffmann, M.; Ma, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of vodobatinib in patients (pts) with chronic phase Philadelphia positive chronic myeloid leukemia (Ph + CML): A sub group analysis by lines of tyrosine kinase inhibitor (TKI) therapy
    Meeting Abstract

    Cortes, J. E.; Saikia, T.; Kim, D. W.; Alvarado, Y.; Nicolini, F. E.; Rathnam, K.; Khattry, N.; Punatar, S.; Apperley, J. F.; Charbonnier, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Pelabresib (CPI-0610) combined with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis: Durability of response and safety beyond week 24
    Meeting Abstract

    Mascarenhas, J.; Kremyanskaya, M.; Patriarca, A.; Gupta, V.; Palandri, F.; Devos, T.; Rampal, R. K.; Talpaz, M.; Vannucchi, A.; Kuykendall, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Raje, N.; Bahlis, N. J.; Costello, C.; Dholaria, B.; Solh, M.; Levy, M. Y.; Tomasson, M. H.; Damore, M. A.; Jiang, S.; Basu, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Outcomes after transplant in relapsed/refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia patients achieving remissions after menin inhibition: SNDX-5613 (revumenib) Ph1 experience
    Meeting Abstract

    Issa, G. C.; Cuglievan, B.; Stein, E.; Arellano, M. L.; Žucenka, A.; Khera, N.; Stone, R. M.; Thirman, M. J.; DiPersio, J. F.; Karras, N.; more...
    Blood (2022)

    Fulltext@MSK | Save